Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug trial aims to ease core autism symptoms in adults

NCT ID NCT06500637

First seen Apr 18, 2026 · Last updated May 20, 2026 · Updated 6 times

Summary

This study tests whether an investigational drug called TB006 can safely improve core autism symptoms in adults aged 18 to 35 with moderate or greater autism severity. About 45 participants will receive either TB006 or a placebo for 14 weeks, and those on placebo may later receive the drug. The main goal is to measure changes in autism severity using clinician-rated scales.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTISM SPECTRUM DISORDER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Rossignol Medical Center

    RECRUITING

    Phoenix, Arizona, 85050, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Rossignol Medical Center

    RECRUITING

    Aliso Viejo, California, 92656, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.